罗兰贝格：2025年地缘政治动荡下制药企业运营绩效提升路径研究报告（英文版）

In research and development (R&D), constrained capital availability has led to cuts in certain areas, particularly cell and gene therapy (CGT). However, major pharmaceutical companies are wary of jeopardizing their future outlook by reducing R&D investments too drastically. New ways of product generation focused on new blockbusters will drive the need for a digitalized and fully transparent value chain of information and material fluxes without creating siloes. This will lead to a hig